Vital Healthcare Prop Tr 주식 (OTC: VTHPF)

에 대한 최신 뉴스 Vital Healthcare Prop Tr (OTC:VTHPF) 주식

Vital Healthcare Property Trust is a healthcare REIT. The vast majority of revenue is generated in Australia, followed by New Zealand. Majority of the company's tenants are for-profit hospitals, followed by medical consultants and nonprofit hospitals. The company's principal activity is the investment in, and management of, high quality real estate in good locations used by healthcare operators or used for healthcare, life sciences and related purposes. It operates in Australia and New Zealand.

VITAL HEALTHCARE PPTY TR by Vital Healthcare Property Trust

Vital Healthcare Property Trust

WIIM

RVPH

Reviva Pharmaceuticals shares are trading lower after the company announced a proposed public offering.

Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) shares traded higher Wednesday, and JPMorgan weighed in on the stock.
What To Know: In the note, the analyst was surprised by Bumble's 30% workforce reduction and even more so by the company's upward revision to its second-quarter revenue and adjusted EBITDA guidance. 
Despite cutting $20 million in marketing spend, Bumble raised its revenue outlook to $244 million to $249 million, up from $235 million to $243 million previously.
The stronger outlook comes as a surprise given that Bumble app downloads are down more than 30% year-over-year. The analyst suggested the full revenue impact of lower marketing spend may still be delayed, as new users often take time to convert into paying subscribers.
Although the workforce cut was larger than expected, Bumble plans to reinvest most of the $40 million in expected annual savings into product and technology. The analyst noted that with Bumble now operating at a margin level similar to Match Group, there may be limited room for further cost-cutting.
Still, JPMorgan cautioned investors not to assume that the improved guidance signals a rebound in the online dating market. Tinder's monthly active users remain stagnant, and Bumble's download trends continue to decline.
BMBL Price Action: Bumble stock closed Wednesday 25.14% higher at $6.52, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
See Also: • <a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

News

Movers

BMBL

Bumble Defies Download Drop With Strong Outlook As Stock Soars

Bit Digital, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"),&nbsp;today announced that its wholly-owned HPC subsidiary, WhiteFiber Inc. ("WhiteFiber"), has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of WhiteFiber's ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

IPOs

BTBT

Bit Digital's Subsidiary WhiteFiber Confidentially Files for IPO with SEC

Burcon NutraScience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BU#TSX">BU</a>) reported quarterly losses of $(0.23) per share. This is a 1050 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $43.000 thousand in sales this quarter.

Earnings

TSX:BU

Burcon NutraScience Q4 EPS $(0.23) Down From $(0.02) YoY, Sales $43.000K

Nature's Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder").
The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes attributable to the resale of the shares of the Company's common stock the Selling Stockholder holds, as well as certain reasonable out-of-pocket expenses incurred by the underwriter. The Company will bear all other costs, fees and expenses incurred in effecting the registration of the shares in the offering.
As part of the offering, the Company has agreed with the Selling Stockholder that it may purchase up to $15.0 million of the shares of its common stock that are subject to the offering from the underwriters at the public offering price as part of the Company's previously announced share repurchase program. However, the Company has not agreed to purchase a minimum amount of shares and may determine to purchase fewer or no shares in this offering. Accordingly, there can be no guarantee that the Company will purchase any shares in this offering and investors should not rely on such agreement as evidence that this offering is more likely to be successful. The Company anticipates that the stock repurchase, if any, would be funded from cash on-hand and funds drawn from its credit facility.
D.A. Davidson &amp; Co. is acting as sole book-running manager and representative of the underwriters for the offering.

Offerings

NATR

Nature's Sunshine Launches Secondary Offering Of 2.85M Shares By Fosun Pharma; Company May Repurchase Up To $15M Under Existing Buyback Program

<a href="https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas</a>

FMCC

FNMA

Reported Earlier: 'Fannie, Freddie Ordered To Find Ways To Count Crypto As An Asset' -Bloomberg

Trex is pleased to reiterate its guidance for full year 2025 revenue growth of 5%-7% and Adjusted EBITDA margin to exceed 31% and is on track to achieve its second quarter revenue guidance of $370 million to $380 million.
 &nbsp;

Guidance

TREX

Trex Reiterates FY25 Guidance For Revenue Growth Of 5%-7% And Adj EBITDA Margin To Exceed 31%; Says On Track To Achieve Q2 Revenue Guidance Of $370M - $380M

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.

Reviva Pharmaceuticals Holdings Announces Proposed Public Offering; No Size Or Amount Disclosed

Golar LNG Limited (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLNG#NASDAQ">GLNG</a>) announces today that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Convertible Senior Notes due 2030 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also intends to grant the initial purchasers of the Notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of the Notes in connection with the offering.

GLNG

Intends To Offer $500M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.82 by 27.27 percent. This is a 0.94 percent decrease over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $832.900 million which beat the analyst consensus estimate of $800.450 million by 4.05 percent. This is a 8.57 percent decrease over sales of $911.000 million the same period last year.

Earnings Beats

Worthington Steel Q4 Adj. EPS $1.05 Beats $0.82 Estimate, Sales $832.900M Beat $800.450M Estimate

Earnings Misses

Jefferies Financial Gr Q2 Adj. EPS $0.40 Misses $0.44 Estimate, Sales $1.63B Beat $1.56B Estimate

CULP

Culper Says 'Due to macro-economic uncertainty and the fluid tariff environment, the Company is not providing specific financial guidance, but only limited annual guidance at this time.'; Sees YoY Sales Growth In Mattress Fabrics Business And For Sales Pressure On Residential Side Of Upholstery Business To Continue

Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 56.41 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $48.773 million which missed the analyst consensus estimate of $52.400 million by 6.92 percent. This is a 1.52 percent decrease over sales of $49.528 million the same period last year.

Culp Q4 EPS $(0.17) Misses $(0.14) Estimate, Sales $48.773M Miss $52.400M Estimate

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
<ul>
<li>First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator</li>
<li>Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin&#xAE; Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old.
COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe. Principal Investigator, Jeffrey Leflein, MD, FAAAAI, FACAAI from the Respiratory Medicine Research Institute of Michigan, in Ann Arbor, Michigan screened the first subject in the study. Additionally, Dr. Doug McMahon, MD, Allergy and Asthma Center in Maplewood, Minnesota and Dr. Jason Ohayon, MD, Hamilton Allergy and Immunology Clinic in Ontario, Canada have been activated and are currently open to recruitment.
"I am thrilled that our talented team of clinicians was the first to screen a subject for the COMFORT Toddlers supplemental safety study and we have several other potential subjects scheduled for screening," said Dr. Leflein. "The initiation of subject enrollment in COMFORT Toddlers reinforces our commitment to peanut-allergic children and their families and is an important step in generating the data needed to potentially advance the Viaskin Peanut patch to market."
COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) safety study designed to supplement the safety and efficacy data from the completed Phase 3 EPITOPE study in the same population. The study duration will be six months followed by an optional 18-month open-label treatment phase, to generate up to 24 or 18 months of active treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively.
"I am very pleased subject screening has commenced in COMFORT Toddlers and look forward to working with my fellow investigators on the efficient enrollment and execution of this important study,"&nbsp;stated Julie Wang, MD, FAAAAI, FACAAI, Professor of Pediatrics, Jaffe Food Allergy Institute, the Icahn School of Medicine at Mount Sinai and Global Principal Investigator for the COMFORT Toddlers study.&nbsp;"The interest we've seen to date further reinforces the significant unmet need that exists for this specific subject cohort."
"Screening our first subject marks a crucial step forward in our mission to develop this potential groundbreaking therapy for food allergic patients, as we are now well underway with both of our core clinical programs," said Daniel Tassé CEO, DBV Technologies. "We believe the data generated through the COMFORT Toddlers study will complete the data set necessary for a Biologics License Application submission to the FDA. DBV is committed to advancing the development of Viaskin Peanut. Our patients and their families are counting on us."

Biotech

General

DBVT

DBV Technologies Announces It Has Screened The First Subject In COMFORT Toddlers Supplemental Safety Study In Peanut Allergic Toddlers 1 – 3 Years Old

Management

Trex CFO Brenda Lovcik Resigns; Bryan Fairbanks Appointed Interim CFO

Bit Digital shares are trading lower after the company announced a public offering.

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 20 years by 3.78% on an annualized basis producing an average annual return of 12.2%. Currently, Linde has a market capitalization of $217.63 billion. 
Buying $1000 In LIN: If an investor had bought $1000 of LIN stock 20 years ago, it would be worth $9,941.67 today based on a price of $460.20 for LIN at the time of writing.
<h3>Linde's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750882533_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

H.B. Fuller shares are trading higher after the company raised its FY2025 Adj. EPS guidance.

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.44 by 37.3 percent. This is a 10.45 percent decrease over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $961.80 million which beat the analyst consensus estimate of $913.70 million by 5.26 percent. This is a 8.20 percent increase over sales of $888.90 million the same period last year.

MLKN

MillerKnoll Q4 Adj. EPS $0.60 Beats $0.44 Estimate, Sales $961.80M Beat $913.70M Estimate

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1275158/000127515825000081/ndls-20250624.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1275158/000127515825000081/ndls-20250624.htm</a>

Comments

Vital Healthcare Prop Tr

뉴스

에 대한 최신 뉴스 Vital Healthcare Prop Tr (OTC:VTHPF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌